(Total Views: 491)
Posted On: 08/15/2019 5:03:12 PM
Post# of 157178
To add to my previous comment......The price tag may have an influence on license deal though.....BP should use this to determine valuation for various indications.
I have always thought that if licensed out it will be priced higher as BP wants as much revenue as possible and likely already owns a large percentage of the other non-MDR2+ patient population. Lower price tag benefits CYDY more of going alone as they could establish a larger market share and likely steal some patients from competition. Word of mouth and referrals would only make mono more likely successful for off-label or once approved. JMO.
I have always thought that if licensed out it will be priced higher as BP wants as much revenue as possible and likely already owns a large percentage of the other non-MDR2+ patient population. Lower price tag benefits CYDY more of going alone as they could establish a larger market share and likely steal some patients from competition. Word of mouth and referrals would only make mono more likely successful for off-label or once approved. JMO.
(1)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
